FGL peptide is a 15-amino-acid research compound derived from the second fibronectin type-III domain of the neural cell adhesion molecule (NCAM). Its mechanism-of-action involves FGFR (fibroblast growth factor receptor) engagement, providing a research-tool angle for probing FGFR signalling in learning, memory, and neurodegeneration contexts.

The compound's development trajectory pursued the neurodegenerative-disease clinical-application angle — specifically mild-to-moderate Alzheimer's disease — through European academic and biotech collaborations that reached Phase II clinical trial around the late 2000s. The Phase II was one of the few peptide-based cognitive-relevance research compounds to reach that clinical-development stage in a Western regulatory context.

The trial enrolled mild-to-moderate Alzheimer's disease patients (typical MMSE score range 12-26) and randomised them to FGL peptide or placebo across a treatment window of several months. The primary endpoints were standard cognitive-endpoint measures including ADAS-Cog (Alzheimer's Disease Assessment Scale — Cognitive subscale) and functional endpoints including ADCS-ADL (Activities of Daily Living scale).

Secondary endpoints included biomarker measures (CSF amyloid-beta and tau where collected), safety and tolerability endpoints, and quality-of-life measures. The trial was double-blind placebo-controlled — meeting the Western regulatory standard for cognitive-endpoint efficacy assessment.

The primary cognitive-endpoint results did not reach statistical significance in the full patient population. Subgroup analyses reported by the trial group suggested that specific patient subgroups may have shown greater response, but subgroup findings from a Phase II with a negative primary endpoint are hypothesis-generating rather than confirmatory.

Safety and tolerability endpoints were favourable — no significant safety signals emerged during the trial. Biomarker measures did not show clear disease-modifying signals.

The overall pattern is one of a null-primary-endpoint trial with acceptable safety, which in the Western regulatory framework does not support progression to Phase III without substantial reformulation, dose-optimisation, or patient-population refinement.

The post-Phase-II development trajectory did not progress to a Phase III trial in Alzheimer's disease. The specific biotech development entity supporting the Phase II wound down its FGL peptide programme, and the research applications since have been academic-context research rather than clinical development.

The compound remains a research-tool of interest in FGFR-signalling and NCAM-derived-peptide research contexts, but the clinical-application trajectory in Alzheimer's disease was not sustained after the negative Phase II result.

The FGL peptide Phase II experience is a useful data-point for the peptide-based cognitive-relevance research field — it demonstrates that a mechanistically-well-characterised research compound with strong preclinical rationale can reach Phase II in Alzheimer's disease and still fail to demonstrate clinical efficacy at that stage. The observation is a caution against extrapolating from preclinical mechanism-strength to clinical-efficacy prediction.

For research purposes the Phase II experience provides a real clinical-context data-point that should inform the interpretation of preclinical mechanism-strong claims about related peptide research compounds. For clinical purposes FGL peptide is not an approved therapy anywhere and remains a research chemical.